Table IV.

Functional enrichment for the target genes of microR-145.

Term	P-value	Genes
hsa05219:Bladder cancer	3.91×10−7	NRAS, CDKN1A, VEGFA, MDM2, CDK4, MYC, MMP1
hsa04550:Signaling pathways regulating	5.82×10−5	NRAS, IGF1R, NANOG, POU5F1, SOX2, MYC, FZD7, KLF4
pluripotency of stem cells
hsa05200:Pathways in cancer	8.73×10−5	NRAS, IGF1R, CDKN1A, HDAC2, VEGFA, MDM2, STAT1,
		CDK4, MYC, FZD7, MMP1, TPM3
hsa04151:PI3K-Akt signaling pathway	1.45×10−4	NRAS, IGF1R, CDKN1A, EIF4E, ITGB8, IFNB1, VEGFA,
		MDM2, CDK4, IRS1, MYC
hsa05220:Chronic myeloid leukemia	1.57×10−4	NRAS, CDKN1A, HDAC2, MDM2, CDK4, MYC
hsa05205:Proteoglycans in cancer	5.32×10−4	NRAS, IGF1R, CDKN1A, NANOG, VEGFA, MDM2, MYC,
		FZD7
hsa05161:Hepatitis B	5.72×10−4	NRAS, CDKN1A, IFNB1, TIRAP, STAT1, CDK4, MYC
hsa05214:Glioma	1.19×10−3	NRAS, IGF1R, CDKN1A, MDM2, CDK4
hsa05202:Transcriptional misregulation in cancer	1.24×10−3	IGF1R, ERG, CDKN1A, FLI1, HDAC2, MDM2, MYC
hsa04115:p53 signaling pathway	1.33×10−3	PPM1D, CDKN1A, SERPINE1, MDM2, CDK4
hsa05218:Melanoma	1.65×10−3	NRAS, IGF1R, CDKN1A, MDM2, CDK4
hsa05206:MicroRNAs in cancer	4.11×10−3	NRAS, CDKN1A, IRS2, PAK4, VEGFA, MDM2, IRS1, MYC
hsa04919:Thyroid hormone signaling pathway	9.03×10−3	NRAS, HDAC2, MDM2, STAT1, MYC
hsa04110:Cell cycle	1.20×10−2	CDKN1A, HDAC2, MDM2, CDK4, MYC
hsa04360:Axon guidance	1.31×10−2	NRAS, PAK4, ROBO2, PPP3CA, SRGAP1
hsa05216:Thyroid cancer	1.84×10−2	NRAS, MYC, TPM3
Shsa04390:Hippo signaling pathway	2.32×10−2	CTGF, SOX2, SERPINE1, MYC, FZD7
hsa05215:Prostate cancer	2.54×10−2	NRAS, IGF1R, CDKN1A, MDM2
hsa05166:HTLV-I infection	3.66×10−2	NRAS, CDKN1A, PPP3CA, CDK4, MYC, FZD7
hsa05169:Epstein-Barr virus infection	4.78×10−2	CDKN1A, HDAC2, MDM2, MYC, MAP2K6

hsa, homo sapiens; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; p53, tumor protein 53; HTLV-I, human T-lymphotropic virus type 1.